Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edArlington, VAAmerican Psychiatric Association2013
   Google Scholar
• KesslerRCThe costs of depressionPsychiatr Clin North Am201235111422370487
   PubMed Web of Science ®Google Scholar
• DrussBGHwangIPetukhovaMSampsonNAWangPSKesslerRCImpairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey ReplicationMol Psychiatry200914772873718283278
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceThe NICE Guideline on the Treatment and Management of Depression in Adults (Updated Edition). NICE2010 Available from: https://www.nice.org.uk/guidance/cg90/evidence/full-guidance-243833293Accessed November 16, 2017
   Google Scholar
• NierenbergAADeCeccoLMDefinitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depressionJ Clin Psychiatry200162Suppl 1659
   PubMedGoogle Scholar
• AngstJKupferDJRosenbaumJFRecovery from depression: risk or reality?Acta Psychiatr Scand19969364134198831856
   PubMed Web of Science ®Google Scholar
• FavaGABechPThe concept of euthymiaPsychother Psychosom20168511526610048
   PubMed Web of Science ®Google Scholar
• ZimmermanMMcGlincheyJBPosternakMAFriedmanMAttiullahNBoerescuDHow should remission from depression be defined? The depressed patient’s perspectiveAm J Psychiatry2006163114815016390903
   PubMed Web of Science ®Google Scholar
• EvansVCLamRWAssessments of functional improvement: self-versus clinician-ratingsMedicographia2014364512520
   Google Scholar
• SaltielPFSilversheinDIMajor depressive disorder: mechanism-based prescribing for personalized medicineNeuropsychiatr Dis Treat20151187588825848287
   PubMed Web of Science ®Google Scholar
• McKnightPEKashdanTBThe importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment researchClin Psychol Rev200929324325919269076
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry2006163111905191717074942
   PubMed Web of Science ®Google Scholar
• MauskopfJASimonGEKalsekarANimschCDunayevichECameronANonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorderDepress Anxiety2009261839718833573
   PubMed Web of Science ®Google Scholar
• KnothRLBolgeSCKimETranQVEffect of inadequate response to treatment in patients with depressionAm J Manag Care2010168e188e19620690785
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice Guideline for the Treatment of Patients with Major Depressive Disorder3rd edAmerican Psychiatric Association2010 Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdfAccessed November 16, 2017
   Google Scholar
• KennedySHLamRWMcIntyreRSCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatmentsCan J Psychiatry201661954056027486148
   PubMed Web of Science ®Google Scholar
• FavaMPharmacological approaches to the treatment of residual symptomsJ Psychopharmacol2006203 Suppl293416644769
   PubMed Web of Science ®Google Scholar
• FavaMRushAJCurrent status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practicePsychother Psychosom200675313915316636629
   PubMed Web of Science ®Google Scholar
• ConnollyKRThaseMEIf at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategiesDrugs2011711436421175239
   PubMed Web of Science ®Google Scholar
• SheehanDVNakagomeKAsamiYPappadopulosEABoucherMRestoring function in major depressive disorder: a systematic reviewJ Affect Disord201721529931328364701
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationPLoS Med200967e100010019621070
   PubMed Web of Science ®Google Scholar
• Symbyax^® (olanzapine and fluoxetine) capsules for oral use [prescribing information]Indianapolis, INLilly USA, LLC2017
   Google Scholar
• ThaseMETrivediMHNelsonJCExamining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studiesPrim Care Companion J Clin Psychiatry200810644044719287552
   PubMedGoogle Scholar
• TrivediMHCorey-LislePKGuoZLennoxRDPikalovAKimERemission, response without remission, and nonresponse in major depressive disorder: impact on functioningInt Clin Psychopharmacol200924313313819318972
   PubMed Web of Science ®Google Scholar
• SteffensDCNelsonJCEudiconeJMEfficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysisInt J Geriatr Psychiatry201126656457220827794
   PubMed Web of Science ®Google Scholar
• FabianTJCainZJAmmermanDImprovement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studiesPrim Care Companion CNS Disord2012146
   Google Scholar
• NelsonJCRahmanZLaubmeierKKEfficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapyCNS Spectr201419652853424642260
   PubMed Web of Science ®Google Scholar
• PandinaGJRevickiDAKleinmanLPatient-rated troubling symptoms of depression instrument results correlate with traditional clinician-and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trialJ Affect Disord20091181–313914619321206
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRMcQuadeRDCarsonWHCorey-LislePKKhanAThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• BermanRMFavaMThaseMEAripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressantsCNS Spectr200914419720619407731
   PubMed Web of Science ®Google Scholar
• KamijimaKHiguchiTIshigookaJAripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)J Affect Disord2013151389990524074484
   PubMed Web of Science ®Google Scholar
• QuirozJATamburriPDeptulaDEfficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trialJAMA Psychiatry201673767568427304433
   PubMed Web of Science ®Google Scholar
• ThaseMEYouakimJMSkubanAEfficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressantsJ Clin Psychiatry20157691224123126301701
   PubMed Web of Science ®Google Scholar
• ThaseMEYouakimJMSkubanAAdjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind studyJ Clin Psychiatry20157691232124026301771
   PubMed Web of Science ®Google Scholar
• FavaMMemisogluAThaseMEOpioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trialAm J Psychiatry2016173549950826869247
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWGuoHEfficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderJ Clin Psychiatry201677337137827046309
   PubMed Web of Science ®Google Scholar
• FavaMRameyTPickeringEKinrysGBoyerSAltstielLA randomized, double-blind, placebo-controlled Phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels?J Clin Psychopharmacol2015351515625422883
   PubMed Web of Science ®Google Scholar
• VietaEThaseMENaberDEfficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressantEur Neuropsychopharmacol201424456457424507016
   PubMed Web of Science ®Google Scholar
• MöllerHJDemyttenaereKOlaussonBTwo Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapyWorld J Biol Psychiatry201516748350125602163
   PubMed Web of Science ®Google Scholar
• TummalaRDesaiDSzamosiJWilsonEHosfordDDunbarGErikssonHSafety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term studyJ Clin Psychopharmacol2015351778125514064
   PubMed Web of Science ®Google Scholar
• BallSDellvaMAD’SouzaDNMarangellLBRussellJMGoldbergerCA double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentJ Affect Disord201416721522324995890
   PubMed Web of Science ®Google Scholar
• BallSGFergusonMBMartinezJMEfficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentJ Clin Psychiatry201677563564227035159
   PubMed Web of Science ®Google Scholar
• BarbeeJGThompsonTRJamhourNJA double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depressionJ Clin Psychiatry201172101405141221367355
   PubMed Web of Science ®Google Scholar
• SanacoraGJohnsonMRKhanAAdjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled studyNeuropsychopharmacology201742484485327681442
   PubMed Web of Science ®Google Scholar
• RichardsCMcIntyreRSWeislerRLisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: results from 2 Phase 3, multicenter, randomized, double-blind, placebo-controlled studiesJ Affect Disord201620615116027474961
   PubMed Web of Science ®Google Scholar
• ThaseMECoryaSAOsuntokunOA randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderJ Clin Psychiatry200768222423617335320
   PubMed Web of Science ®Google Scholar
• MahmoudRAPandinaGJTurkozIKosik-GonzalezCCanusoCMKujawaMJGharabawi-GaribaldiGMRisperidone for treatment-refractory major depressive disorder: a randomized trialAnn Intern Med2007147959360217975181
   PubMed Web of Science ®Google Scholar
• SheehanDVThe Anxiety DiseaseNew YorkCharles Scribner & Sons1983
   Google Scholar
• SheehanDVHarnett-SheehanKRajBAThe measurement of disabilityInt Clin Psychopharmacol199611Suppl 38995
   PubMed Web of Science ®Google Scholar
• SheehanKHSheehanDVAssessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability ScaleInt Clin Psychopharmacol2008232708318301121
   PubMed Web of Science ®Google Scholar
• SpielmansGIBermanMILinardatosERosenlichtNZPerryATsaiACAdjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesPLoS Med2013103e100140323554581
   PubMed Web of Science ®Google Scholar
• Abilify^® (aripiprazole) tablets; Abilify Discmelt^® (aripiprazole) orally disintegrating tablets; Abilify^® (aripiprazole) oral solution; Abilify^® (aripiprazole) injection for intramuscular use only [prescribing information]Tokyo, JapanOtsuka Pharmaceutical Co., Ltd.2017
   Google Scholar
• Rexulti^® (brexpiprazole) tablets, for oral use [prescribing information]Tokyo, JapanOtsuka Pharmaceutical Co., Ltd.2017
   Google Scholar
• Eli Lilly and CompanyLilly announces edivoxetine did not meet primary endpoint of Phase III clinical studies as add-on therapy for major depressive disorder [press release]Indianapolis, INEli Lilly and Company2013 Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751Accessed November 17, 2017
   Google Scholar
• BeckACrainALSolbergLIUnützerJGlasgowREMaciosekMVWhitebirdRSeverity of depression and magnitude of productivity lossAnn Fam Med20119430531121747101
   PubMed Web of Science ®Google Scholar
• WilesNJMulliganJPetersTJSeverity of depression and response to antidepressants: GENPOD randomised controlled trialBr J Psychiatry2012200213013622194183
   PubMed Web of Science ®Google Scholar
• KirschIDeaconBJHuedo-MedinaTBScoboriaAMooreTJJohnsonBTInitial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug AdministrationPLoS Med200852e4518303940
   PubMed Web of Science ®Google Scholar
• FountoulakisKNVeronikiAASiamouliMMöllerHJNo role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysisAnn Gen Psychiatry20131212623941527
   PubMed Web of Science ®Google Scholar
• AdlerDAMcLaughlinTJRogersWHChangHLapitskyLLernerDJob performance deficits due to depressionAm J Psychiatry200616391569157616946182
   PubMed Web of Science ®Google Scholar
• TrivediMHMorrisDWWisniewskiSRIncrease in work productivity of depressed individuals with improvement in depressive symptom severityAm J Psychiatry2013170663364123558394
   PubMed Web of Science ®Google Scholar
• SonneCCarlssonJBechPElklitAMortensenELTreatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy – a randomised studyBMC Psychiatry201616138327825327
   PubMed Web of Science ®Google Scholar
• BechPMeasurement-Based Care in Mental DisordersCham, SwitzerlandSpringer International Publishing AG2016
   Google Scholar